Dihexas trajectoryfrom claims of being seven orders of magnitude more potent than BDNF in rodents to a failed Phase 2/3 trial and retracted foundational researchexemplifies this valley of death. This pattern demands particular caution when extrapolating from compelling animal data to expectations for human cognitive benefit
Registered Phase I study A safety and pharmacokinetics study was registered, but public results sufficient to establish a safety profile have not been posted
Timeline & Results 1 Week vs 1 Month (Before-and-After Expectations) Most before & after stories pair injections with a calorie deficit, protein targets, training, steps, and sleep
How AOD-9604 compares with related compounds and approved drugs
Detection indicators: bone density (lumbar spine, hip), bone turnover markers (OC, CTX), bone microstructure (number, thickness, and gaps of bone trabeculae), and skeletal mechanical strength